Fifth Question of the Day September 7, 2013 How will Imprimis Pharmaceuticals, Inc. with its exclusive relationship with PCCA to commercialize compounded drug formulations utilizing the FDA 505(b)(2) drug develop and predicted to become a large pharmaceutical company in a relatively short period of time impact compounding pharmacies?

For more information on Imprimis --

News

Imprimis' Platform Set To Bring Library Drug Formulations Quickly To Market

By M.E. Garza: Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) has seen its stock rise from about $5.25 per share in February at the time of the NASDAQ listing to around $9 per share and is one of the...

Imprimis acquires intellectual property from Novel Drug Solutions, Eye Care Northwest

Imprimis Pharmaceuticals, focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships, has acquired intellectual property from Nov...

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval...

Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT

SAN DIEGO, Aug. 5, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) drug develop...

Imprimis to initiate phase III study of drug formulation Impracor

Imprimis Pharmaceuticals has received approval from the Institutional Review Board (IRB) to initiate Phase III clinical trial protocol of its new topical non-steroidal anti-inflammatory drug (NSAID) c...

Imprimis Pharmaceuticals acquires Buderer intellectual property assets

Imprimis Pharmaceuticals has acquired the intellectual property (IP) rights related to proprietary innovations from the compounding pharmacy operations of Ohio-based Buderer Drug, a compounding pharma...

Imprimis Management Discovers And Adds Significant Value In Bankrupt Company Restart

By MarketScanners:Wall Street is littered with failed companies that had great business plans, but did not have management capable of fulfilling the plan's promise. Good investors know management team...

Imprimis acquires IP rights to ophthalmic compound

USA-based Imprimis Pharmaceuticals (Nasdaq: IMMY), which is focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships and by uti...